Peio Aristu-Zabalza
Hospital Clínic de Barcelona · 19 works · 288 citations · h-index 6
Top works
- Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
- Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension
- The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer
- Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical
- A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease
- Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension
- Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis
- GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH
- Nanoparticles as an efficient strategy to eliminate senescent brain endothelial cells
- GTX-011 improves fibrosis and hepatic stellate cells phenotype in human precision cut liver slices
- UN MODELO MICROFLUÍDICO DE TEJIDO CIRRÓTICO HUMANO REVELA LA CAPACIDAD ANTIFIBRÓTICA DE LIRAGLUTIDA MEDIANTE LA DESACTIVACIÓN DE LAS CÉLULAS HEPÁTICAS ESTRELLADAS Y EL REMODELADO DE LA MATRIZ EXTRACELULAR
- FRI-421 GLP-1 agonist lowers portal pressure by modulating hepatic vascular tone in a toxin-induced cirrhotic rat model
- Enhancing Safety and Efficacy of Senolytic Therapies with Advanced Controlled Release Strategies
- FRI-110-A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease
- THU-176 Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension
- Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling